2018

Walker AJ, Peacock C, Pedergnana V, STOP-HCV Consortium, Irving WL. Host genetic factors associated with hepatocellular carcinoma: a systematic review’. J Viral Hepatatis  Feb 3

Bonsall D, Black S, Howe AYM, Chase R, Ingravallo P, Pak I, Brown A, Smith D, Bowden R, Barnes E, and the STOP HCV Consortium ‘Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse’ Infection and Drug Resistance (In press)

Smith D, Magri A, Bonsall D, Ip C, Trebes A, Brown A, Piazza P, Bowden R, STOP-HCV Consortium, Ansari MA, Simmonds P, Barnes E ‘Resistance analysis of genotype 3 HCV reveals subtypes inherently resistant to NS5A inhibitors’. Hepatology Feb 9

Ramamurthy N, Marchi E, Ansar MA, Pedergnana V, Mclean A, Hudson E, STOP HCV consortium, Bowden R, Spencer CCA, Barnes E, Klenerman P ‘Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C’ Hepatology March 13

2017

 Wymant C, Hall M, Ratmann O, Bonsall D, Golubchik T, Cesare M, Gall A, Cornelissen M, Fraser C, The Stop-HCV Consortium , The Maela Pneumococcal Collaboration, and The BEEHIVE Collaboration. PHYLOSCANNER: Analysing Within- and Between-Host Pathogen Genetic Diversity to Identify Transmission, Multiple Infection, Recombination and Contamination Infection and Drug Resistance. Mol Biol Evol. Nov 23

Scott RA et al.Direct Acting Anti-virals Treatment for hepatitis C results in a significant and rapid reduction in MRI measures of hepatic angio-architecture’  Gastroenterology (In press)

Filipe A,  ‘Response to DAA Therapy in the NHS England Early Access Programme for Rare HCV Subtypes from Low and Middle Income Countries’ J Hepatol 67(6):1348-1350

Barnes E and Hudson E. 'STOP-HCV - Stratified Medicine to Optimise Treatment for Hepatitis C Virus Infection' Impact, 6: 81-83(3)

Ansari MA et al. A genome-to-genome analysis shows the impact of the innate and adaptive immune system on the hepatitis C virus’Nature Genetics 49: 666–673 

2016

Thomson E et al. 'Comparison of next generation sequencing technologies for the comprehensive assessment of full-length hepatitis C viral genomes’ Journal of Clinical Microbiology 54 (10): 2470-84

van Wilgenburg B et al. 'MAIT cells are activated during human viral infections’ Nature Communications 23 (7):11653.

Ansari MA et al. 'Genome-to-genome virus-host analysis reveals HCV genotype 3 viral polymorphisms linked to viral load and to host HLA Class I/II and IL28B alleles’ Journal of Hepatology 64:S419 

Bonsall D et al. 'Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR’ Emerging Infectious Diseases 2016 22(4): 671-678

Witteveldt J et al. 'Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing’ Antimicrobial Agents & Chemotherapy 60 (5): 2981-92 

Pedergnana V et al. ‘Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a’Hepatology 64 (4):1377-8

Martin N et al. ‘Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation’ Journal of Hepatology 2016 65(1):17-25

2015

Bonsall D et al. ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens’ F1000Research 4:1062

Foster GR et al. 'Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection’ Gastroenterology 149(6): 1462-70

Publications associated with work from the STOP-HCV Consortium: 

Cheung MC et al. 'Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis’ Journal of Hepatology 2016 65 (4): 741-7

Platt L et al. 'Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis’ Lancet Infectious Diseases 2016 16 (7): 797-80

Foster GR et al. ‘Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis’ Journal of Hepatology 2016 64 (6): 1224-31

Iles JC et al. 'Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing’ Journal Clinical Microbiology 2015 53 (10):3155-6

van de Ven N et al. 'Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus’ Hepatology 2015 61(4):1174-82

Matthews PC et al. 'Screening and treatment for hepatitis C: a balanced perspective' British Medical Journal 2015 24;350

Messina JP et al. 'Global distribution and prevalence of hepatitis C virus genotypes’ Hepatology 2015 61(1):77-87